Search

Your search keyword '"Johannessen CM"' showing total 39 results

Search Constraints

Start Over You searched for: Author "Johannessen CM" Remove constraint Author: "Johannessen CM"
39 results on '"Johannessen CM"'

Search Results

1. Art as Research in Semiotic Technology: The Case of David Hockney’s Digital Art

3. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.

4. Systematic identification of biomarker-driven drug combinations to overcome resistance.

5. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers.

6. Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.

7. CloneSifter: enrichment of rare clones from heterogeneous cell populations.

8. Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine.

9. Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.

10. Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases.

11. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.

12. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.

13. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

14. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.

15. Next-generation characterization of the Cancer Cell Line Encyclopedia.

16. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.

17. Mutational processes shape the landscape of TP53 mutations in human cancer.

18. A Convergence-Based Framework for Cancer Drug Resistance.

19. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors.

20. Creation of Novel Protein Variants with CRISPR/Cas9-Mediated Mutagenesis: Turning a Screening By-Product into a Discovery Tool.

21. Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.

22. Characterizing genomic alterations in cancer by complementary functional associations.

23. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.

24. A functional landscape of resistance to ALK inhibition in lung cancer.

25. Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.

26. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

27. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.

28. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

29. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

30. MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.

31. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

32. A public genome-scale lentiviral expression library of human ORFs.

33. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

34. TORC1 is essential for NF1-associated malignancies.

35. A negative feedback signaling network underlies oncogene-induced senescence.

36. Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.

37. Regulation of mTOR and cell growth in response to energy stress by REDD1.

38. The NF1 tumor suppressor critically regulates TSC2 and mTOR.

39. REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.

Catalog

Books, media, physical & digital resources